[HTML][HTML] Thrombosis in myeloproliferative neoplasms during cytoreductive and antithrombotic drug treatment
A state‐of‐the‐art lecture titled “Myeloproliferative Neoplasm‐associated Thrombosis” was
presented at the ISTH congress in 2021. We summarize here the main points of the lecture
with two purposes: to report the incidence rates of major thrombosis in polycythemia vera
and essential thrombocythemia and to discuss to what extent cytoreductive therapy and
antithrombotic drugs have reduced the incidence of these events. Unfortunately, the
incidence rate of thrombosis remains high, ranging between 2 and 5/100 person‐years. It is …
presented at the ISTH congress in 2021. We summarize here the main points of the lecture
with two purposes: to report the incidence rates of major thrombosis in polycythemia vera
and essential thrombocythemia and to discuss to what extent cytoreductive therapy and
antithrombotic drugs have reduced the incidence of these events. Unfortunately, the
incidence rate of thrombosis remains high, ranging between 2 and 5/100 person‐years. It is …